188 related articles for article (PubMed ID: 16126022)
21. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
[TBL] [Abstract][Full Text] [Related]
22. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
Schwertz DW; Badellino KO
J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
[TBL] [Abstract][Full Text] [Related]
23. [Statins in stroke prevention].
Gedikli O; Baykan M
Anadolu Kardiyol Derg; 2008 Jun; 8(3):217-22. PubMed ID: 18524729
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
25. Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Chapman N; Chang CL; Caulfield M; Dahlöf B; Feder G; Sever PS; Poulter NR
Ethn Dis; 2011; 21(2):150-7. PubMed ID: 21749017
[TBL] [Abstract][Full Text] [Related]
26. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
J Hypertens; 2011 Mar; 29(3):592-9. PubMed ID: 21297502
[TBL] [Abstract][Full Text] [Related]
27. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
28. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
[TBL] [Abstract][Full Text] [Related]
29. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
30. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Arca M; Gaspardone A
Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
[TBL] [Abstract][Full Text] [Related]
31. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Ray KK; Cannon CP
Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
[TBL] [Abstract][Full Text] [Related]
32. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
Szramka M; Harriss L; Ninnio D; Windebank E; Brack J; Skiba M; Krum H
Int J Cardiol; 2007 Apr; 117(2):287-91. PubMed ID: 16889854
[TBL] [Abstract][Full Text] [Related]
33. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
[TBL] [Abstract][Full Text] [Related]
35. Statin therapy and stroke prevention: what was known, what is new and what is next?
Mazighi M; Lavallée PC; Labreuche J; Amarenco P
Curr Opin Lipidol; 2007 Dec; 18(6):622-5. PubMed ID: 17993806
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
37. Expanding roles for atorvastatin.
Singh V; Deedwania P
Drugs Today (Barc); 2008 Jun; 44(6):455-71. PubMed ID: 18596999
[TBL] [Abstract][Full Text] [Related]
38. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
39. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
[TBL] [Abstract][Full Text] [Related]
40. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.
Alber HF; Frick M; Suessenbacher A; Doerler J; Schirmer M; Stocker EM; Dichtl W; Pachinger O; Weidinger F
Am Heart J; 2006 Jan; 151(1):139. PubMed ID: 16368305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]